TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33176232
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment for mBC
Study: 33176232
Drug: Third-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line treatment for mBC
Study: 33171419
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (hysterectomy, myomectomy, or UAE)
Study: 35907513
Drug: Metformin 500mg
Normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg by mouth three times a day for 30 to 36 months
Study: 32928570
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) associated with Stabilization Exercises (SE)
Study: 34303323
Drug: Jyoti-Trataka yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jyoti-Trataka yoga (daily 55-min sessions for one month)
Study: 34303323
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (administered oral hypoglycemic drugs only)
Study: 34303323
Drug: Between-group comparison
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between-group comparison post-treatment
Study: 36810360
Drug: Positive expiratory
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive expiratory pressure (PEP) therapy
Study: 33332779
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg per kilogram of body weight intravenously)
Study: 32945218
Drug: Metformin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1500 mg) plus myoinositol (4 g) per day
Study: 32945218
Drug: Myoinositol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoinositol (4 g) per day
Study: 33090016
Drug: Fast acting
Normalized name: 4-Way Fast Acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast acting insulin aspart (FA)
Study: 32623833
Drug: Micellar water,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micellar water, cream, and serum
Study: 34928336
Drug: Pooled Higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled Higher Doses (PHD) group (≥1 000 IU/day, n = 349)
Study: 34928336
Drug: Pooled Higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled Higher Doses (PHD) group (≥1 000 IU/day)
Study: 32730089
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cervical (C3-C4), cervicothoracic (C7-T1) and thoracic spine (T5-T6) thrust joint manipulation
Study: 32721948
Drug: ZNF217 targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZNF217 targeting with preexisting therapies, such as the Akt inhibitor triciribine
Study: 32568205
Drug: Escitalopram (n=13;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (n=13; average dose=7.3 mg)
Study: 32568205
Drug: Sertraline (n=11;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (n=11; average dose=31.8 mg)
Study: 32568205
Drug: Nicergoline (n=9;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (n=9; average dose=14.5 mg)
Study: 33723687
Drug: Vaginal fractional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal fractional CO2 laser therapy
Study: 33774639
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of collagen peptides (CP)
Study: 33774639
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of collagen peptides (CP)
Study: 33913736
Drug: Artesunate tablet
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate tablet (50 mg two times daily) combined with HAART
Study: 35788775
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice to isocalorically increase protein intake to ≥ 1.2 g/kg aBW/d (Protein + ; n = 84)
Study: 35880828
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (4 g/d; 0.60 g EPA/d, 0.28 g DHA/d, 0.45 g astaxanthin/d)
Study: 35712946
Drug: Auricular bloodletting
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular bloodletting combined with auricular point sticking once a week for 4 weeks (treatment group 1)
Study: 35712946
Drug: Auricular bloodletting
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular bloodletting combined with auricular point sticking twice a week for 4 weeks (treatment group 2)
Study: 35712946
Drug: Auricular bloodletting
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular bloodletting combined with auricular point sticking three times a week for 4 weeks (treatment group 3)
Study: 32740716
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with daily traditional experiential music listening
Study: 33201130
Drug: Intermittent Pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Pneumatic Compression (IPC) in addition to standard prophylaxis with anti-embolic stockings and low-molecular-weight heparin
Study: 33970256
Drug: Depot buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot buprenorphine (weekly or monthly)
Study: 33970256
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (daily)
Study: 32376759
Drug: Nasal fentanyl
Normalized name: fentanyl Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal fentanyl (NF) and buccal midazolam (BM) administered by family members
Study: 32376759
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (BM) alone
Study: 32376759
Drug: Standard breakthrough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard breakthrough medication by nurses
Study: 36510345
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol
Study: 36460236
Drug: Silver Modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Modified Atraumatic Restorative Treatment (SMART)
Study: 36351436
Drug: Genicular nerves
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genicular nerves block (20 ml ropivacaine 0.2%)
Study: 36351436
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (150 ml ropivacaine 0.2%)
Study: 35869721
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal therapy (RCT) (203 cases)
Study: 36109696
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment based on botulinum toxin or oral drugs after 3 months
Study: 35461287
Drug: Standard measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard measles vaccine
Study: 35379019
Drug: Triamcinolone Hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Hexacetonide (TH) 40 mg
Study: 33017047
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ketamine
Study: 35276467
Drug: Saliravira® package
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliravira® package plus routine treatments of COVID-19
Study: 35276467
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments of COVID-19 alone
Study: 32486877
Drug: Serum total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum total bilirubin tertile 3 (12.9–34.1 μmol/L)
Study: 32486877
Drug: Direct bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct bilirubin tertile 3 (2.5–24.8 μmol/L)
Study: 33555697
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment (10 to 15 sessions)
Study: 35299177
Drug: Site-specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-specific therapy based on gene expression profiling (GEP)
Study: 35595223
Drug: GnRHa alone
Normalized name: GnRH pharmaccine
DrugBank: GnRH pharmaccine (DB05815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa alone (0.2 mg of triptorelin)
Study: 35595223
Drug: Dual trigger
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual trigger (0.2 mg of triptorelin plus 2000 IU of hCG)
Study: 34735862
Drug: Targeted education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted education on the use of oral HIV self-test kits for their partners, along with up to five oral HIV self-test kits.
Study: 32430507
Drug: EPOCH-vorinostat (EPOCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH-vorinostat (EPOCH plus 300 mg vorinostat on days 1 to 5 of each cycle)
Study: 32430507
Drug: Low diagnosis-to-treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low diagnosis-to-treatment interval (DTI)
Study: 32430507
Drug: Preprotocol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprotocol therapy
Study: 35983429
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1.5 mg kg−1 followed by 4 mg kg−1 h−1 continuous infusion)
Study: 34759182
Drug: High-molecular-weight hyaluronate
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-molecular-weight hyaluronate injection (20 mg)
Study: 34759182
Drug: Low-molecular-weight hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight hyaluronate injection (20 mg)
Study: 34759182
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (10 sessions)
Study: 32660521
Drug: Low-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume preparation
Study: 32660521
Drug: High-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume preparation
Study: 38721650
Drug: Flexible take-home
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible take-home dosing buprenorphine/naloxone
Study: 32691178
Drug: Low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methadone (LDM)
Study: 34938043
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (BTX)
Study: 38587822
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses)
Study: 36483295
Drug: NESA neuromodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESA neuromodulation treatment (NNT)
Study: 32282852
Drug: Metformin 1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,700 mg/day
Study: 32282852
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of linagliptin/metformin
Study: 35664940
Drug: Acacia (Acacia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia (Acacia nilotica Linn.) pod's sitz bath (30g) plus vaginal cotton pessary (5 ml) once daily for 10 days
Study: 35664940
Drug: Placebo (palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (palm sugar powder 30g solution for sitz bath plus vaginal cotton pessary same as Acacia group)
Study: 32538007
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus western medication (levamlodipine maleate 2.5 mg once daily)
Study: 32538007
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus western medication
Study: 32538007
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (levamlodipine maleate 2.5 mg once daily)
Study: 32719045
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone (250 mg on day 1 followed by 80 mg on days 2-5) with or without tocilizumab (8 mg/kg body weight, single infusion) if respiratory condition did not improve sufficiently (in 43%).
Study: 32719045
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone with or without tocilizumab.
Study: 34216815
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg/three times-week
Study: 34216815
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg/once a week
Study: 34216815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (full dose arm)
Study: 34216815
Drug: Circulating sex
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating sex hormones
Study: 32664003
Drug: Continuing sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing sertraline
Study: 32664003
Drug: Combining sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combining sertraline with mirtazapine
Study: 32664003
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to mirtazapine after initial failure to remit on sertraline
Study: 35550149
Drug: Oral Veillonella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Veillonella nakazawae
Study: 32741031
Drug: Warfarin (775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (775 patients, INR goal 2.5)
Study: 33405993
Drug: TQ‐A3334 (0.2‐1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ‐A3334 (0.2‐1.8 mg)
Study: 33405993
Drug: TQ‐A3334 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ‐A3334 (1.0 to 1.8 mg)
Study: 33405993
Drug: TQ‐A3334 (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ‐A3334 (1.2 mg) with food
Study: 33554566
Drug: Low vitamin-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin-D levels (<50 nmol/L)
Study: 33554566
Drug: Normal vitamin-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vitamin-D levels (>50 nmol/L)
Study: 34674368
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg time-release melatonin
Study: 33028293
Drug: Reduced duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced duration of antibiotic treatment
Study: 33028293
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration of antibiotic treatment (control group)
Study: 34819131
Drug: Lithium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (300 mg)
Study: 32524888
Drug: Elective replacement
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective replacement of peripheral intravenous cannula (72–96 h)
Study: 32524888
Drug: Standard replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard replacement of peripheral intravenous cannula
Study: 32524888
Drug: Elective replacement
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective replacement of peripheral intravenous cannula
Study: 36453237
Drug: Water Vapor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Vapor Therapy (Rezum procedure)
Study: 35507830
Drug: Exposure-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based treatment for perfectionism
Study: 36857393
Drug: ATG 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 4.5 mg/kg
Study: 34275562
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg every 8 hours for five days, then 20 mg daily for three months
Study: 35392744
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once daily
Study: 36203828
Drug: Home-based transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based transcranial direct current stimulation (tDCS) self-administered daily for 30 min with 2 mA
Study: 35454326
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (C) with perioperative opioids and metamizole/acetaminophen
Study: 35377106
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard care with swaddling, oral sucrose, and sucking)
Study: 33038825
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (200 mg/kg)
Study: 33038825
Drug: Betaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (2 g/kg)
Study: 33038825
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ascorbic acid (200 mg/kg) and Betaine (2 g/kg)
Study: 36103158
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg/d
Study: 36103158
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/d
Study: 34312921
Drug: 3 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml/kg 5% Dextrose
Study: 34312921
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg 5% Dextrose
Study: 33389390
Drug: Emotion coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion coaching parenting intervention (Tuning in to Kids® program), 6 weekly sessions
Study: 34329897
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GE) 600 mg
Study: 32694214
Drug: Dapagliflozin/Saxagliptin (DAPA/SAXA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/Saxagliptin (DAPA/SAXA) 10/5 mg
Study: 32144165
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin (DAPA) 10 mg
Study: 32043211
Drug: Suramin (P2Y2R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin (P2Y2R inhibitor, 100 μM)
Study: 32991462
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.1 mg)
Study: 34696892
Drug: Regorafenib at
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib at 160 or 120 mg daily, 3 weeks on/1 week off
Study: 34696892
Drug: Tamoxifen at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen at 40 mg daily
Study: 33827639
Drug: Prebiotic (oligofructose‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (oligofructose‐enriched inulin; 16 g/day)
Study: 33985385
Drug: -40 mmHg
Normalized name: Loving Comfort Knee High 30-40 mmHg Beige L
Approvals — FDA: no, EMA: no, PMDA: no
Description: -40 mmHg INP treatment for 1 hour twice daily for 12 weeks
Study: 33985385
Drug: -10 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: -10 mmHg INP sham control treatment for 1 hour twice daily for 12 weeks
Study: 39536246
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements
Study: 36484214
Drug: Xience drug-eluting
Normalized name: Ruxience
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xience drug-eluting stent (DES)
Study: 33756301
Drug: Cigalike (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigalike (18 mg/mL)
Study: 33756301
Drug: Tank (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tank (18 mg/mL)
Study: 33756301
Drug: Tank (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tank (6 mg/mL)
Study: 34622734
Drug: CET monotherapy
Normalized name: CET
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CET monotherapy
Study: 34622734
Drug: AAU monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAU monotherapy
Study: 34622764
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily for 12 weeks, followed by continued treatment through Week 64
Study: 32414338
Drug: Management algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests.
Study: 34974413
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg OD)
Study: 33539318
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycosides (TG) 20 mg tablet three times per day for 24 weeks
Study: 33539318
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (iv.MP) 500 mg once per week for 6 weeks followed by 250 mg per week for 6 weeks
Study: 33539318
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (iv.MP)
Study: 33235030
Drug: Dapansutrile 2000
Normalized name: Dapansutrile
DrugBank: Dapansutrile (DB16130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapansutrile 2000 mg
Study: 34574458
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) - Angelicae Sinensis Radix